Loading news...
WW International, Inc. (NASDAQ: WW - Get Free Report) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 1,593,503 shares, a growth of 28.9% from the January 29th total of 1,236,706 shares. Based on an average daily trading volume, of 328,331 shares, the days-to-cover
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026.
The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life
A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone
WW International, Inc. (NASDAQ: WW - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $27.60 and traded as high as $29.40. WW International shares last traded at $28.44, with a volume of 251,911 shares changing hands. Analyst Upgrades and Downgrades WW has
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last
WW International (WW) delivered a strong Q3, exceeding revenue and EBITDA expectations, driven by its Clinical Business. WW faces ongoing challenges, including declining Behavioral subscribers and cautious Q4 guidance, which may keep investors wary until trends improve. Key catalysts ahead include FDA decisions on GLP-1 compounding, expanded insurance coverage, and new partnerships with pharma and insurance providers.
WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.
WW International, Inc. ( WW ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants David Helderman - Director of Investor Relations Tara Comonte - President, CEO & Director Felicia DellaFortuna - Chief Financial Officer Jon Volkmann - Chief Operations Officer Conference Call Participants Alex Fuhrman - Lucid Capital Markets, LLC, Research Division Justin Ages - CJS Securities, Inc. Nathaniel Feather - Morgan Stanley, Research Division Presentation Operator Good morning, and welcome to WeightWatchers International's Third Quarter 2025 Results Conference Call. [Operator Instructions] Please note this event is being recorded.
End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA 1 of $43 million and Adjusted EBITDA Margin 1 of 24.9% Narrowing 2025 Guidance to the higher end of previous ranges for Revenue and Adjusted EBITDA1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the third quarter of fiscal 2025 ended September 30, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company's Corporate Website . Third Quarter 2025 Overview Q3 reflected a significantly strengthened balance sheet as the Company's first full quarter post-restructuring, with total debt reduced by more than 70% (~$1.1 billion) and Cash at quarter end increasing to $170 million from $152 million at the end of Q2.
Shares of WW International rose nearly 6% in premarket trading on Monday after the company announced a new partnership with Amazon to deliver GLP-1 weight-loss drugs and other prescription medications directly to its members.
Weight management company WW International, also known as WeightWatchers (NASDAQ:WW), has partnered with Amazon Pharmacy to streamline access to weight management medications for WeightWatchers Clinic members. Under the partnership, members can view real-time medication availability, compare delivery options, and receive prescriptions through Amazon Pharmacy.
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon Pharmacy , a full-service online pharmacy. Through this collaboration, WeightWatchers Clinic members will gain access to real-time medication availability, automatic coupon savings, and fast, reliable home delivery for weight management medications.
Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic
Members See 46% Improvement in Work-Related Quality of Life and 53% Improvement in Overall Quality of Life
New analyst coverage sparks fresh interest in WW and BULL as both stocks show stable 2025 forecasts despite recent declines.
Groundbreaking Programme Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions Groundbreaking Programme Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions